The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells by Bleloch, Jenna Susan et al.
Bleloch et al. Cell Death Discovery            (2019) 5:60 
https://doi.org/10.1038/s41420-019-0139-9 Cell Death Discovery 
ART ICLE Open Ac ce s s
The palladacycle complex AJ-5 induces
apoptotic cell death while reducing
autophagic flux in rhabdomyosarcoma
cells
Jenna Susan Bleloch1, André du Toit2, Liezl Gibhard3, Serah Kimani1, Reyna Deeya Ballim1, Minkyu Lee1,
Angelique Blanckenberg4, Selwyn Mapolie 4, Lubbe Wiesner3, Ben Loos2 and Sharon Prince1
Abstract
Rhabdomyosarcoma (RMS) forms in skeletal muscle and is the most common soft tissue sarcoma in children and
adolescents. Current treatment is associated with debilitating side effects and treatment outcomes for patients with
metastatic disease are dismal. Recently, a novel binuclear palladacycle, AJ-5, was shown to exert potent cytotoxicity in
melanoma and breast cancer and to present with negligible adverse effects in mice. This study investigates the anti-
cancer activity of AJ-5 in alveolar and embryonal RMS. IC50 values of ≤ 0.2 µM were determined for AJ-5 and it
displayed a favourable selectivity index of >2. Clonogenic and migration assays showed that AJ-5 inhibited the ability
of RMS cells to survive and migrate, respectively. Western blotting revealed that AJ-5 induced levels of key DNA
damage response proteins (γH2AX, p-ATM and p-Chk2) and the p38/MAPK stress pathway. This correlated with an
upregulation of p21 and a G1 cell cycle arrest. Annexin V-FITC/propidium iodide staining revealed that AJ-5 induced
apoptosis and necrosis. Apoptosis was confirmed by the detection of cleaved PARP and increased levels and activity of
cleaved caspases-3, -7, -8 and -9. Furthermore, AJ-5 reduced autophagic flux as shown by reduced LC3II accumulation
in the presence of bafilomycin A1 and a significant reduction in autophagosome flux J. Finally, pharmacokinetic
studies in mice show that AJ-5 has a promising half-life and that its volume of distribution is high, its clearance low
and its intraperitoneal absorption is good. Together these findings suggest that AJ-5 may be an effective
chemotherapeutic with a desirable mechanism of action for treating drug-resistant and advanced sarcomas.
Introduction
Rhabdomyosarcoma (RMS) originate in skeletal muscle
and is the most common soft tissue sarcoma in children,
adolescents and young adults1,2. It is classified as either
embryonal (eRMS) or alveolar (aRMS), with each exhi-
biting distinct histological, molecular and pathological
characteristics. Whereas eRMS affects predominantly
infants and children, aRMS occur primarily in adolescents
and young adults. Furthermore, eRMS comprises
approximately 67% of RMS cases with common sites of
tumorigenesis including the head, neck and genitourinary
system. On the other hand, aRMS accounts for approxi-
mately 30% of RMS cases with arms and legs often being
sites of primary disease3–5. RMS thus contributes to a
considerable loss of years of life in comparison to other
cancers as it largely affects children and adolescents.
The current standard treatment for patients with RMS
is multimodal therapy consisting of local control with
surgery and/or radiation therapy in conjunction with
multi-agent chemotherapy6. Since the 1970s, disease
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control for patients with localized or completely resected
RMS has been achieved with combinational chemother-
apy most commonly including vincristine, dactinomycin
(actinomycin D) and cyclophosphamide (VAC)7. How-
ever, this treatment regimen has had limited success for
patients with regional spreading, incomplete resection or
metastasis8. Furthermore, these drugs are associated with
debilitating side effects including nausea, vomiting, fati-
gue, mouth ulcers, stomach ache, hair loss, bone marrow
suppression, peripheral neuropathy and haemorrhagic
cystitis9–12. Continued collaborative efforts to find more
effective treatments with fewer side effects is therefore
important, especially for metastatic RMS.
The use of transition metal complexes as potential
therapeutics and in diagnostic medicine is of consider-
able importance. Platinum drugs, particularly cisplatin,
are the mainstay of metal-based compounds in the
treatment of cancer. However, due to dose-related
adverse effects and multi-drug resistance associated
with this line of therapy there has been an ongoing
search for alternative metallic compounds with
improved anti-cancer and pharmacokinetic properties
and distinct mechanisms of action13. Palladium-based
complexes have recently been reported to exert sig-
nificant cytotoxicity in cancer cells14. Importantly, stu-
dies have shown that while both platinum and palladium
compounds induce DNA damage, the palladium com-
pounds exert a much greater degree of cytotoxicity in
cancer cells15,16. Moreover, numerous palladium com-
plexes exhibit strong cytotoxic effects in cells resistant
to cisplatin17. Together these results suggest that pal-
ladium complexes may exert cytotoxicity through a
mechanism different to that of platinum compounds
and that they may prove to be less toxic and more
effective for the treatment of aggressive cancers.
Recently, AJ-5, a novel binuclear palladacycle complex
with 1,2-bis(diphenylphosphino)ethane as co-ligand was
shown to exert potent anti-tumour activity in advanced
melanoma and breast cancer cells with very promising
in vivo clearance of advanced melanoma18,19. In the
present study we therefore explored these questions in
RMS and other sarcoma subtypes. We show here for the
first time that AJ-5 displays potent and selective cyto-
toxicity at sub-micromolar concentrations (≤0.2 µM)
against aRMS and eRMS cells and inhibits their ability
to survive, proliferate and migrate. We show that AJ-5
induces double-stranded DNA breaks (DSBs) which
triggers the canonical DSBs ataxia telangiectasia muta-
ted serine/threonine kinase (ATM)/checkpoint kinase 2
(Chk2) pathway as well as the p38/mitogen-activated
protein kinase (MAPK) stress signalling pathway leading
to a G1 cell cycle arrest, reduction in autophagic flux and
induction of apoptosis. Furthermore, AJ-5 shows effi-
cacy in a range of sarcoma subtypes and displays a
promising pharmacokinetic profile in healthy mice. This
study provides evidence that AJ-5 has promising ther-
apeutic potential for the treatment of RMS and a range
of other sarcoma subtypes.
Results
AJ-5 shows potent and selective cytotoxicity against RMS
cells
Here we investigated the anti-tumour effects of the
binuclear palladacycle complex, AJ-5, in RMS cells. To
this end, MTT assays were performed on aRMS (RH30
and AX-OH-1 cell lines) and eRMS (RD and FL-OH-1
cell lines) cells treated with a range of AJ-5 concentrations
(0.1–1.0 μM) for 48 h. IC50 concentrations of ≤0.2 µM
were obtained for all cell lines (Fig. 1a). Light microscopy
images of RMS cells treated for 24 and 48 h with their
respective IC50 concentrations show the impact of AJ-5
on cell viability and morphology (Fig. 1b). To determine
the selectivity of AJ-5 for RMS cells, IC50 values were
determined in non-malignant fibroblasts (FG0 and DMB)
and mouse myoblasts (C2C12). Results show that AJ-5 is
less cytotoxic in the non-malignant cells with a selectivity
index (SI) of >2 in all cases (Fig. 1c). Interestingly, there is
growing evidence that mesenchymal stem cells are the cell
of origin for specific sarcoma types including RMS20,21,
and compared to the other non-malignant cells tested, the
mesenchymal stem cells (A100021501) were the most
sensitive to AJ-5.
AJ-5 inhibits the ability of RMS cells to survive, proliferate
and migrate
To explore the potential impact of AJ-5 on the long-
term fate of RMS cells, clonogenic assays were per-
formed22. Figure 2a shows representative images and
quantification of colonies formed over 7–21 days after 24
h of AJ-5 treatment. It is evident that AJ-5 significantly
inhibits the ability of RMS cells to survive and proliferate.
Indeed, for all except one RMS cell line tested, there was a
significant decrease in colony area at ¼ IC50 treatment
and only a few or no RMS cell colonies formed at IC50
concentrations. Importantly, the ability of the non-
malignant C2C12 myoblasts to survive and proliferate
was not significantly hindered after 24 h of 0.3 µM AJ-5
(Fig. 2b). This is at least 1.5 times higher than the IC50
values obtained for the RMS cells. To further explore the
anti-cancer activity of AJ-5, RMS cells were exposed for
24 h to IC50 concentrations of the drug and scratch
motility assays were performed. Fig. 2c shows that AJ-5
reduced the migratory ability of all RMS cells tested.
Taken together, these data suggest that AJ-5 inhibits the
ability of RMS cells to survive, proliferate and migrate.
To further explore the mechanisms by which AJ-5
exerts its cytotoxicity, the aRMS cell line RH30 and the
eRMS cell line RD were used for further characterization.
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Fig. 1 AJ-5 shows potent and selective cytotoxicity against aRMS and eRMS cells. a MTT cell viability assays of aRMS cell lines, RH30 and AX-OH-
1, and eRMS cell lines, RD and FL-OH-1, treated with a range of AJ-5 concentrations (0.1–1.0 µM) or vehicle for 48 h. Graphs show mean cell viability as
a percentage of vehicle control ± SEM for each concentration of AJ-5 determined from three independent experiments performed in quadruplicate.
A curve was fitted to determine the IC50 concentration of AJ-5 for each cell line. b Representative light microscopy images (×200; EVOS XL AMEX1000
Core Imaging System) of aRMS and eRMS cell lines treated with their respective IC50 concentrations of AJ-5 or vehicle for 24 and 48 h. c MTT cell
viability assays of non-malignant human fibroblast cell lines, FG0 and DMB, mouse myoblast cell line, C2C12, and mesenchymal stem cell line,
A10021501, treated with AJ-5 and IC50 concentrations determined as described in a above. Selectivity indices (SIs) were determined for each RMS cell
line by dividing the IC50 of each non-malignant cell line by the IC50 of each RMS cell line
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Fig. 2 AJ-5 inhibits the ability of RMS cells to survive, proliferate and migrate. a Representative images and quantification of clonogenic assays
of eRMS and aRMS cells treated with vehicle, ¼ IC50, ½ IC50 or IC50 concentrations of AJ-5 for 24 h and then replated at low densities in drug-free
medium and left for 7–21 days for colonies to form. Colonies were stained with crystal violet and images from three independent repeats were
quantified using the ImageJ plugin ColonyArea. The graph represents the mean colony area ± SEM of each treatment condition as a percentage of
the vehicle control. b The same as a above for the non-malignant mouse myoblast cell line C2C12, but treated with vehicle, 0.15 µM, 0.3 µM, or 0.6
µM AJ-5. c Representative images (×200; EVOS XL AMEX1000 Core Imaging System) and quantification of scratch motility assays of eRMS and aRMS
cells pre-treated with IC50 concentrations of AJ-5 or vehicle for 24 h and then replated at 100% confluency in drug-free medium. After cell adherence,
a sterile 2 µL pipette tip was used to make a linear wound in the cell monolayer and cells were treated with 10 µg/mL mitomycin C to inhibit
proliferation. Cells were imaged at 0, 3, 6, 9, 12 and 24 h post wound formation. Total area migrated was calculated by subtracting the wound area at
each time point from the wound area at time 0 h, which is represented in the graphs as mean area migrated ± SEM pooled from three independent
repeats. Data were analysed using GraphPad Prism 6.0 and a parametric unpaired t-test was performed where *p < 0.05, **p < 0.01, ***p < 0.001
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AJ-5 activates the DNA damage and p38 MAPK pathways
in RMS cells
γH2AX is a robust marker of DSBs23 and western
blotting and immunocytochemistry revealed a dose-
dependent increase in levels of γH2AX (Fig. 3a) and an
accumulation of distinct γH2AX foci in the nuclei of AJ-
5-treated cells (Fig. 3b), respectively. Furthermore, AJ-5
treatment led to increased levels of phosphorylated ATM
and its downstream target CHK2 as well as phosphory-
lated p38 (Fig. 3c). AJ-5 thus activated the canonical DSB
and p38 MAPK stress signalling pathways. Both of these
pathways converge on p53, which ordinarily plays an
important role in transcriptionally activating the cyclin-
dependent kinase p2124. However, both the RMS cell lines
used in this study harbour p53 mutations that result in
high levels of inactive p5325. Importantly, p21 levels
increased at the IC50 concentrations of AJ-5 and this
response was particularly pronounced after 24 h of
treatment (Fig. 3c). These results suggest that p21 levels
increase in a p53-independent manner.
AJ-5 triggers a G1 cell cycle arrest and induces apoptosis
and necrosis
To investigate the effect of AJ-5 on cell cycle progres-
sion, FACS analyses were performed on RMS cells treated
with drug for 24 and 48 h. Results show that AJ-5 induces
a G1 cell cycle arrest in both cell lines at the expense of
the S phase (Fig. 4a). This correlated with a decrease in
levels of cyclin A and cyclin B, which are required for
progression through the S and G2/M phases, respec-
tively26 (Fig. 4b). The sub-G1 peaks seen in Fig. 4a sug-
gested that AJ-5 treatment leads to cell death. Indeed,
Annexin V-FITC assays confirm that AJ-5 induces
apoptotic and necrotic cell death (Fig. 4c).
AJ-5 triggers the intrinsic and extrinsic apoptosis pathways
in RMS cells
To confirm that AJ-5-induces apoptosis, RD and RH30
cells were treated with AJ-5 and biological, molecular and
biochemical markers of apoptosis were investigated by
light microscopy, western blotting and enzymatic
Caspase-Glo assays, respectively. The results show that
AJ-5 induced characteristic features of apoptosis includ-
ing membrane blebbing and cell shrinkage (Fig. 5a). In
addition, AJ-5 treatment led to increased levels and
activity of cleaved caspase-8 and caspase-9, the effectors
of the extrinsic and intrinsic pathways, respectively
(Fig. 5b, c). This correlated with increased levels of the
active (cleaved) forms of the executioner caspases-3/7 and
their substrate poly (ADP-ribose) polymerase (PARP)
(Fig. 5b, c)27,28. Interestingly, we observed an ~20 kDa
band above the 18 kDa active cleaved caspase-8 fragment.
A similar band has also been reported by other
researchers and it has been suggested that it represents an
intermediate product of procaspase-8 processing29,30.
Importantly, caspases-8 and -9 were more robustly acti-
vated in RD cells treated with AJ-5 than those treated with
IC50 doxorubicin, a drug commonly used in the treatment
of RMS and used as a positive control in apoptosis assays
(Fig. 5c). Together these results show that AJ-5 induces
cell death in RMS cells, in part, through the extrinsic and
intrinsic apoptotic pathways.
AJ-5 induces several markers of autophagy in RMS cells
We next investigated whether AJ-5 induced autophagy
because large vacuolar structures and acidic vesicles were
observed in RMS cells treated with this drug (Supple-
mentary Fig. S1A). To this end, western blotting and
immunocytochemistry were performed with an antibody
to microtubule-associated protein light chain 3 (LC3).
Supplementary Figure S1B shows that LC3II (the autop-
hagosomal membrane bound form of LC3) was induced
in both RMS cell lines in a time- and dose-dependent
manner. Furthermore, supplementary Fig. S1C shows
distinct puncta, presumed to represent LC3II aggregates
conjugated to autophagosomal membranes, in RD and
RH30 cells from as early as 6 h after AJ-5 treatment.
AJ-5 reduces autophagic flux in RD and RH30 cells
The detection of LC3II alone does not distinguish
between autophagy induction and cessation in the
downstream steps of autophagy. We therefore next
determined the impact of AJ-5 treatment on autophagic
flux by measuring the levels of p62, a receptor of poly-
ubiquitinated proteins. The rationale for this is based on
observations that upon autophagy induction, p62 is
incorporated within an autophagosome and degraded
within an autolysosome31. The turnover of p62 is there-
fore considered an indicator of autophagic flux. Interest-
ingly, Fig. 6a shows that whereas AJ-5 appears to reduce
autophagic flux in RH30 cells, it increases autophagic flux
in RD cells. To confirm the above data, levels of LC3II
were determined by western blotting in the presence and
absence of bafilomycin A1 which blocks the autophagy
pathway by inhibiting fusion of autophagosomes with
lysosomes32. An accumulation of LC3II in the presence of
this inhibitor is therefore considered evidence of autop-
hagic flux. Consistent with our p62 data in RH30 cells, AJ-
5 treatment followed by bafilomycin A1 exposure led to
decreased levels of LC3II (Fig. 6b). Interestingly, contrary
to our p62 data in RD cells, in the presence of bafilomycin
A1, AJ-5 treatment led to a negligible change in LC3II
compared with vehicletreated cells (Fig. 6b). We therefore
further investigated the impact of AJ-5 on autophagic flux
in the RD cell line by performing single-cell autophago-
some flux analyses. Our results reveal that RD cells
are characterized by a predominant autolysosomal pool
(nA= 83 autolysosomes/cell), with only a very minor pool
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Fig. 3 AJ-5 activates the DNA damage and the p38 MAPK pathways. a γH2AX protein levels detected by western blotting in RH30 (aRMS) and
RD (eRMS) cells treated with vehicle (V), 0.1 µM or IC50 AJ-5 for 24 and 48 h. p38 was used as a loading control. Densitometry readings were obtained
using ImageJ and protein expression levels are represented as a ratio of protein of interest/p38 normalized to the vehicle control sample (where
possible). Blots are representative of at least two independent repeats. b Representative confocal immunofluorescence maximum intensity projection
images (×630; Carl Zeiss LSM 510) of RH30 and RD cells treated with IC50 AJ-5 or vehicle for 24 h and γH2AX detected with a fluorophore-conjugated
Cy3 secondary antibody. Nuclei of cells were stained with DAPI. Scale bar is 20 µM. Box plots represent quantification of γH2AX levels per treatment
condition as mean nuclear Cy3 fluorescence from 20 fields of view from three independent repeats. Data were analysed using GraphPad Prism 6.0
and a parametric unpaired t-test was performed where *p < 0.05, **p < 0.01, ***p < 0.001. cWestern blot analyses with antibodies to key DNA damage
and stress signalling pathway proteins: p-ATM, p-Chk2, p-p38, p53, and p21. RH30 and RD cells were treated with AJ-5 and protein expression
quantified as described above in a. Broken lines in western blots shown in this figure indicate where lanes not relevant were removed
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Fig. 4 (See legend on next page.)
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of autophagosomes and lysosomes per cell (Fig. 6c).
Moreover, the cells are characterized by a basal autop-
hagosome flux J of 6.3 autophagosomes per hour per cell.
Upon AJ-5 treatment, however, both autolysosome pool
size as well as autophagosome flux significantly decreased.
This suggests that AJ-5 negatively impacts the rate of
autophagosome synthesis, which supports the data
showing that in the presence of bafilomycin A1, AJ-5
treatment does not lead to LC3II accumulation (Fig. 6b).
Together these data suggest that AJ-5 reduces autophagic
flux in RH30 and RD cells.
AJ-5 is cytotoxic in a range of sarcoma subtypes
To investigate if the therapeutic potential of AJ-5 could
be extended to other sarcoma subtypes, chondrosarcoma
(SW1353), liposarcoma (SW872), synovial sarcoma
(SW982), fibrosarcoma (HT1080) and osteosarcoma
(MG-63) cells were treated with the drug as described
earlier and MTT assays were performed. Our results show
that an IC50 of <0.3 µM was obtained for all the sarcoma
cell lines tested (Supplementary Fig. S2A) and a favour-
able SI of >2 was achieved when calculated relative to the
combined IC50 values for the normal fibroblasts (FG0 and
DMB). However, a sub-optimal SI between 1 and 1.5 was
obtained when the IC50 values for the sarcoma cells were
expressed relative to the mesenchymal stem cells
(A10021501) (Supplementary Fig. S2B). This raises the
interesting possibility that AJ-5 may be effective against
the cells of origin of these sarcoma subtypes which may be
of therapeutic benefit. Furthermore, clonogenic assays
reveal that as little as a ¼ IC50 concentration of AJ-5
significantly reduced the ability of cells of all sarcoma
subtypes to survive and proliferate (supplementary
Fig. S2C). AJ-5 therefore shows potent selective cyto-
toxicity against a number of diverse sarcoma subtypes and
may therefore have broad therapeutic potential.
Pharmacokinetic (PK) profile of AJ-5 in healthy mice
Given its importance to the drug discovery process, we
next tested the in vivo PK profile of AJ-5 in whole blood of
MF1 mice following a single dose of 2 mg/kg intravenous
(IV), 2 mg/kg intraperitoneal (IP) or 20 mg/kg oral (PO)
for a period of 24 h. The blood concentration–time curve
of AJ-5 over a 24 h period and the calculated PK para-
meters are shown in Supplementary Fig. S3 and Table S1.
For IV administration, AJ-5 illustrated a long half-life
(>10 h), which is most likely due to the low clearance (9.2
mL/min/kg) and a high volume of distribution (8.8 L/kg).
The exposure of AJ-5 following the IP dose of 2 mg/kg
was eight-fold higher compared to the PO dose of 20 mg/
kg with an area under the curve of 88 and 11min.µM/L,
respectively. The data obtained for the IP group in healthy
mice correlated well with our previously observed in vivo
efficacy of AJ-5 in advanced melanoma18.
Discussion
RMS is the most common soft tissue sarcoma found in
children and adolescents and while the current treatment
for localized tumours results in a high overall survival
rate, the chemotherapeutic agents used are associated
with debilitating adverse effects10,33–36. Moreover, more
than 15% of patients present with metastatic disease and
there has been limited improvement in the treatment of
patients with recurrent and metastatic disease37–41. The
current study provides several lines of evidence that the
binuclear palladacycle AJ-5 may be a promising che-
motherapeutic to treat aRMS and eRMS cells as well as a
range of other sarcoma subtypes. Furthermore, we pro-
vide novel and interesting mechanisms by which AJ-5
functions (see Fig. 7).
Platinum compounds such as cisplatin have been used
successfully as anti-tumour agents but they have been
associated with severe toxicity and tumour drug resis-
tance42. Palladium compounds have been proposed as
more effective alternatives because they appear to be
more active at lower concentrations with less severe side
effects43,44. Cisplatin is occasionally used to treat RMS6
and was reported to have an IC50 of >0.5 µM after
4–5 days of treatment in a range of RMS cell lines
including RD and RH30 cells45,46. Our study shows that
after only 2 days of AJ-5 treatment, IC50 values of ≤0.2
µM were obtained in the RD and RH30 cells. This
suggests that AJ-5 displays more potent anti-cancer
activity at much lower concentrations over a shorter
(see figure on previous page)
Fig. 4 AJ-5 triggers a G1 cell cycle arrest and induces apoptotic and necrotic cell death in RH30 and RD cells. a Flow cytometry analyses of
cells treated with vehicle or IC50 AJ-5 for 24 and 48 h. Graphs represent the mean proportion of cells ± SEM at each phase of the cell cycle pooled
from three independent repeats. b Western blot analyses of protein harvested from cells treated as indicated and incubated with antibodies against
cell cycle markers cyclin A and cyclin B1. p38 was used as a loading control. Densitometry readings were obtained using ImageJ and protein
expression levels are represented as a ratio of protein of interest/p38 normalized to the vehicle control sample. Blots are representative of at least two
independent repeats. Broken lines indicate where lanes not relevant were removed. c Flow cytometric analyses of cells treated with vehicle or IC50
AJ-5 and stained with Annexin V-FITC and PI. Graphs represent the mean ± SEM percentage of viable (lower left-hand quadrant), apoptotic (lower
right-hand quadrant+ upper right-hand quadrant) and necrotic (upper left-hand quadrant) cells from three independent experiments. For a and c
data were analysed using GraphPad Prism 6.0 and a parametric unpaired t-test was performed where *p < 0.05, **p < 0.01, ***p < 0.001
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period than cisplatin in these RMS cells. Furthermore,
we show that AJ-5 displays a selectivity index of ≥2,
which suggests that it has specificity for RMS cells47,48.
Indeed, whereas AJ-5 treated RMS cells were unable to
form any colonies, mouse myoblasts treated with 1.5–3
times higher concentrations formed colonies with areas
comparable to that obtained for vehicletreated cells
(Fig. 2a). Furthermore, mesenchymal stem cells from
different sources are thought to represent the target cell
of origin for a variety of human sarcomas and our cell
viability assays (Fig. 1c) show that the A100021501
mesenchymal stem cells were the most sensitive non-
malignant cell line to AJ-5 treatment20. This suggests
that AJ-5 may have the ability to selectively target the
sarcoma-initiating cell which could prove to be advan-
tageous and more efficacious than current therapies.
Taken together these findings support evidence that,
compared to platinum compounds, palladium com-
plexes display superior anti-cancer activity and that they
may associate with fewer side effects.
While tumours initially respond to proapoptotic thera-
pies, they frequently acquire the ability to bypass the
apoptotic pathway and develop drug resistance leading to
tumour recurrence49,50. It is thus predicted that drugs that
can trigger alternative or multiple programmed cell death
(PCD) pathways such as autophagy (PCD type II) and
programmed necrosis (PCD type III) would be more
efficacious51. The annexin V-FITC assays in Fig. 4c reveal
that AJ-5 induces not only a significant apoptotic popu-
lation but also a significant cell population which could
represent necrosis, programmed necrosis (necroptosis)
and/or secondary necrosis which occurs when there is
insufficient clearance of apoptotic cells49,52. Interestingly,
we have preliminary western blot data that show that AJ-5
treatment causes an increase in phosphorylated receptor-
interacting serine/threonine protein kinase 3 (RIP3), a
critical component of necroptosis, as well as increased
levels of active (phosphorylated) mixed lineage kinase
domain-like protein (MLKL), a key executioner of
necroptosis (data not shown). The possibility that AJ-5
may induce necroptosis is exciting; however, to confirm
this annexin V-FITC assays of AJ-5-treated cells in the
presence of necrostatin-1 and the pan-caspase inhibitor
Z-VAD-fmk will need to be performed.
Here we show for the first time that AJ-5 reduces
autophagic flux in both aRMS and eRMS cells. This is an
important finding because autophagy has been reported
to promote cell survival and chemotherapeutic drug
resistance in a number of sarcomas, including RMS, and
thus autophagy has been identified as a drug target to
treat sarcomas50,51,53. For example, the autophagy inhi-
bitor, chloroquine, enhanced RMS cell death induced by
ciclopirox olamine, bortezomib and 17-DMAG and sti-
mulation of autophagy by rapamycin prevented this54,55.
Consistent with our findings, palladium nanoparticles
have recently been shown to block autophagic flux in Hela
cells as shown by increased LC3II/I ratios, reduced
degradation of p62 and autophagosome accumulation56.
It is important to note that AJ-5 induces autophagy PCD
in melanoma and breast cancer cells, which suggests that
the effect of palladium complexes on autophagy may be
cancer type specific.
In conclusion, we show that AJ-5 may be a promising
chemotherapeutic to treat aRMS and eRMS because it
displays potent and selective cytotoxicity at sub-
micromolar concentrations and inhibits the ability of
RMS cells to survive, proliferate and migrate. Importantly,
AJ-5 induces apoptosis and reduces autophagic flux and it
displays a favourable pharmacokinetic and safety profile.
Materials and methods
Cell culture
RH30 human aRMS cells (kindly provided by
Associate Professor Judith Davie, Southern Illinois
University), AX-OH-1 human aRMS and FL-OH-1
human eRMS cells (kindly provided by Professor Ste-
fan Bath, University of Cape Town) were cultured in
Roswell Park Memorial Institute Medium (RPMI)-1640
(Sigma Aldrich, Missouri, USA). RD human eRMS cells
(ATCC® CCL-136™), FG0 and DMB human skin fibro-
blasts (kindly provided by Associate Professor Denver
Hendricks, University of Cape Town), mouse myoblast
(see figure on previous page)
Fig. 5 AJ-5 triggers the intrinsic and extrinsic apoptosis pathways in RMS cells. a Representative light microcopy images (×200; EVOS XL
AMEX1000 Core Imaging System) showing the morphology of RH30 and RD cells treated with vehicle, 0.1 µM or IC50 AJ-5 for 24 and 48 h. Numbered
circles correspond to magnified images on the right, which highlight characteristic apoptotic morphology including membrane blebbing and cell
shrinkage. b Western blot analyses of protein harvested from cells treated as in a and incubated with antibodies as indicated. p38 was used as a
loading control and densitometry readings were obtained using ImageJ. Protein expression levels are represented as a ratio of protein of interest/p38
normalized to vehicle control samples (where possible). Blots are representative of at least two independent repeats. Broken lines indicate where
lanes not relevant were removed. c Caspase-Glo assays showing the enzymatic activity of caspase-3/7, caspase-8 and caspase-9 for cells treated with
vehicle or IC50 AJ-5. Doxorubicin was included as a positive control for caspase-8 and -9 assays at the IC50 concentration (0.5 µM) established in the
cell lines tested. Graphs represent the mean fold change of caspase activity ± SEM pooled from three independent repeats. Data were analysed using
GraphPad Prism 6.0 and a parametric unpaired t-test was performed where *p < 0.05, **p < 0.01, ***p < 0.001
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Fig. 6 AJ-5 reduces autophagic flux in RD and RH30 cells. a Western blotting of p62/SQSTM1 protein levels in RH30 and RD cells treated with
vehicle (V), 0.1 µM or IC50 AJ-5 for 24 and 48 h. b Western blotting showing LC3I and LC3II protein levels in RH30 and RD cells treated with vehicle (V)
or IC50 AJ-5 for 24 h followed by 2 h of treatment with 200 nM bafilomycin A1. For western blots, p38 was used as a loading control and densitometry
readings were obtained using ImageJ. Protein expression levels are represented as a ratio of protein of interest/p38 normalized to vehicle control
sample. Blots are representative of at least two independent repeats. c Representative single-cell fluorescence maximum intensity projection
micrographs (×630; Carl Zeiss LSM 780; scale bar is 20 µM) and pool size quantification of autophagy pathway intermediates: autophagosomes (GFP-
LC3, nA) (indicated with white arrows in the merged image), autolysosomes (LysoTracker Red, nAL) and lysosomes (merged, nL). Autophagosome flux
J was calcuclated. Data were analysed using GraphPad Prism 6.0 and a parametric unpaired t-test was performed *p < 0.05, **p < 0.01, ***p < 0.001.
# compared to untreated control, * compared to vehicle control
Bleloch et al. Cell Death Discovery            (2019) 5:60 Page 11 of 16
Official journal of the Cell Death Differentiation Association
cells (ATCC® CRL-1772™), human mesenchymal stem
cells A10021501 (kindly provided by Professor Michael
Pepper, University of Pretoria and confirmed to meet
the criteria to be defined as mesenchymal stem cells as
set out by the Mesenchymal and Tissue Stem Cell
Committee of the International Society for Cellular
Therapy57), HT1080 human fibrosarcoma cells (ATCC®
CCL-120™), SW1353 human chondrosarcoma cells
(ATCC® HTB-94™), SW982 human synovial sarcoma
cells (ATCC® HTB-93™), SW872 human liposarcoma
(ATCC® HTB-92™) and MG-63 human osteosarcoma
cells (kindly provided by Associate Professor
Philippa Hulley, University of Oxford) were cultured in
Dulbecco’s modified Eagle’s medium (Sigma Aldrich).
All culture medium was supplemented with 10%
heat-inactivated foetal bovine serum, 100 U/mL peni-
cillin and 100 μg/mL streptomycin. Cells were main-
tained at 37 °C in a 95% air and 5% CO2 humidified
incubator. Medium was replaced every 2 to 3 days and
cells were routinely subjected to mycoplasma tests.
Only mycoplasma free cells were used in experiments.
Cell morphology was monitored using an Olympus
CKX41 inverted microscope (MSAC Ltd, UK) and
imaged with an EVOS™ XL AMEX1000 Core Imaging
System (Thermo Fisher Scientific, Massachusetts,
USA).
Cell treatments
AJ-5, synthesized as previously described18, was dis-
solved in dimethyl sulfoxide (DMSO) (D8418; Sigma
Aldrich) to give a 5 mM AJ-5 stock which was stored at
room temperature (RT) and used within 5 days. AJ-5 was
diluted in cell culture medium to achieve the desired final
concentration and a vehicle control (DMSO) of the same
concentration was prepared simultaneously. Cells were
treated at a confluency of 60%. For western blot experi-
ments to determine autophagy flux, cells were treated
with 200 nM bafilomycin A1 (B1793; Sigma Aldrich) for 2
h post AJ-5 treatment. Doxorubicin (z/26/0167; Teva
Pharmaceutical Industries Ltd, Israel) was used as a
positive control in Caspase-Glo experiments at a con-
centration of 0.5 µM.
Cell viability assays
Cells were seeded in 96-well plates and treated the next
day with a range of AJ-5 concentrations (0.1–1.0 μM) or
vehicle (1.0 μM DMSO) for 48 h. Cell viability was mea-
sured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
trazolium bromide (MTT) assay (11465007001; Sigma
Aldrich) according to the manufacturer’s instructions.
Mean cell viability was calculated as a percentage of the
mean vehicle control. At least three independent experi-
ments in quadruplicate were performed from which the
half maximal inhibitory concentration (IC50) was deter-
mined using GraphPad Prism version 6.0 (GraphPad
Software, California, USA). The selectivity index (SI) was
determined by dividing the IC50 of a normal cell line by
the IC50 of a cancer cell line.
Clonogenic assays
Cells were seeded in 6-well plates and treated the fol-
lowing day with IC50, ½ IC50, ¼ IC50 AJ-5 and vehicle.
After 24 h, 800–4000 cells were seeded in 35 mm dishes in
drug-free medium. Formation of colonies were monitored
and after 7–21 days cells were fixed with 3:1 methanol:
acetic acid and stained with 0.5% crystal violet (Sigma
Aldrich) in 100% methanol. Colonies were imaged and
percentage colony area was determined using ImageJ
v1.50i58 and the plugin ColonyArea59. Colony area was
Fig. 7 Proposed model for AJ-5 in RMS. At low concentrations
(≤0.2 µM) in aRMS and eRMS cells AJ-5 induces DSBs leading to
increased levels of γH2AX and activation of both the canonical DSB
pathway (ATM/Chk2) and the p38/MAPK stress signalling pathway.
This results in a p21-induced G1 cell cycle arrest followed by the
activation of the extrinsic and intrinsic apoptotic pathways and a
reduction in autophagic flux
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determined for each drug concentration and expressed as
a percentage of vehicletreated control.
Scratch motility assay
Cells were seeded in 6-well plates and treated with IC50
AJ-5 and vehicle for 24 h. Cells were then collected,
counted and replated to achieve 100% confluency in a 24-
well plate. The following day a sterile 2 µL pipette tip was
used to make a vertical scratch in the cell monolayer of
each well and the cells treated with 10 µM mitomycin C
(M4287; Sigma Aldrich) to inhibit proliferation. Cells
were imaged at 0, 3, 6, 9, 12 and 24 h post wound for-
mation and ImageJ v1.50i58 was used to calculate the area
of the scratch. The total areas migrated was determined
by subtracting the area for a specific time point from the
area measured at 0h.
Western blot analyses
Cells were harvested after exposure to IC50 AJ-5, 0.1
µM AJ-5 or vehicle (DMSO) for 24 and 48 h. Cells were
lysed at 4 °C in whole-cell lysis buffer (0.125 M Tris-HCl
pH 6.8, 4% SDS, 0.2% glycerol, 0.1% β-mercaptoethanol
and a pinch of bromophenol blue) and boiled for
10 min. Proteins were resolved by SDS-PAGE (6–15%
gels) and transferred to Hybond ECL membranes
(Amersham, UK). The membranes were incubated with
primary antibodies: rabbit polyclonal antibodies to
phospho-histone H2A.X (Ser139) (#2577), phospho-
chk2 (Thr68) (#221), phospho-p38 MAPK (Thr180/
Tyr182) (#9211), cleaved caspase-3 (Asp175) (#9661),
PARP (#9542), caspase-9 (#9502), LC3B (#2775), p38
MAPK (#9212), rabbit monoclonal antibody to cleaved
caspase-7 (Asp198) (D6H1) (#8438), mouse monoclonal
antibodies to phospho-ATM (Ser1981) (D6H9) (#5883),
Cyclin B1 (V152) (#4135), Caspase-8 (1C12) (#9746),
SQSTM1/p62 (D5L7G) (#88588) from Cell Signaling
Technology (Massachusetts, USA); mouse monoclonal
antibody to p53 (DO-1) (sc-126), rabbit polyclonal
antibodies to p21 (C-19) (sc-397), cyclin A (H-432) (sc-
751), cyclin B1 (H-433)(sc-752), PARP-1 (H-250) (sc-
7150) from Santa Cruz Biotechnology (Texas, USA);
rabbit polyclonal antibody to p38 MAP kinase (M0800)
from Sigma Aldrich. After primary antibody incubation,
membranes were incubated with goat anti-rabbit or goat
anti-mouse HRP-conjugated secondary antibodies (Bio-
Rad Laboratories, California, USA). Antibody reactive
proteins were visualized by enhanced chemilumines-
cence using SuperSignal West Pico Chemiluminescent
Substrate Kit (Thermo Fisher Scientific) or Wester-
nBright ECL HRP Substrate Kit (Advansta, California,
USA). Densitometry readings were obtained using
ImageJ v1.50i58 and protein expression levels were
represented as a ratio of protein of interest/p38 loading
control normalized to the vehicletreated control sample
where appropriate. All blots are representative of at least
two independent repeats.
Immunofluorescence
Cells were plated on glass coverslips and treated with
IC50 AJ-5 or vehicle. Cells were fixed with ice-cold 100%
methanol at −20 °C for 5 min followed by blocking and
permeabilization with 0.2% Triton-X-100/5% bovine
serum albumin in phosphate-buffered saline (PBS) for 30
min at RT. Slides were incubated with antibodies against
phospho-histone H2A.X (#2577) (1:500) or LC3B (#2775)
(1:200) (Cell Signaling Technology) in blocking buffer
overnight at 4 °C. After PBS washes coverslips were
incubated with donkey anti-rabbit or donkey anti-mouse
Cy3-conjugated secondary antibodies (Jackson Immu-
noResearch Laboratories Inc., Pennsylvania, USA) diluted
1:1000 for 1.5 h in blocking buffer at RT. A secondary-
antibody-only control was always included in these
experiments. Cells were then counterstained with
Hoechst (33342; Invitrogen, California, USA) for 10 min
at RT in the dark, washed with PBS and then coverslips
were mounted onto glass slides using Mowiol mounting
medium. Cells were imaged with an LSM 510 confocal
microscope (Carl Zeiss, Germany) using a Plan-
Apochromat ×63/1.40 oil DIC objective. Multiple z lay-
ers were acquired with 1 µM step width. Images were
processed using ZEN 2012 imaging software (Carl Zeiss)
and maximum intensity projections were generated. For
quantification, mean fluorescence was measured from at
least 20 fields of view per treatment condition and pooled
from three independent repeats.
Cell cycle analysis
Cells were seeded and treated the following day with
IC50 AJ-5 and vehicle for 24 and 48 h, trypsinized, washed
with PBS, counted and permeabilized in 70% EtOH at
−20 °C overnight. Cells were pelleted and treated with 50
μg/mL RNase (Fermentas, Massachusetts, USA) in PBS at
37 °C for 15min and then stained with propidium iodide
(PI). A minimum of 50 ,000 cells/sample were subjected
to analysis using a Becton Dickinson FACSCalibur flow
cytometer (Becton Dickinson, New Jersey, USA) with a
488 nm coherent laser. The data were acquired using
CellQuest Pro version 5.2.1. software (Becton Dickinson)
and the analyses were done using ModFit version 2.0.
software (Verity Software House Inc, Maine, USA).
Annexin V-FITC assays
Cells were seeded, trypsinized, washed and counted as
described for cell cycle analysis. The FITC Annexin V/
Dead Cell Apoptosis kit (V13242; Thermo Fisher Scien-
tific) was used according to the manufacturer's instruc-
tions. A negative control of unstained cells and positive
controls of cells treated with 3% formaldehyde for 30 min
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on ice and stained with either PI or Annexin V were used
to gate the flow cytometer for viable, early apoptotic, late
apoptotic, and necrotic cell populations. Samples were
subjected to FACS analyses as described for cell cycle
analysis. Data were obtained and analysed using CellQuest
Pro version 5.2.1. software.
Caspase activity assays
Cells were seeded and treated for 24 h with IC50 AJ-5,
vehicle or 0.5 µM (IC50) doxorubicin which was included
and as a positive control. Cells were trypsinized, washed
and counted and caspase-8, -9, and -3/7 activity was
measured using the appropriate Caspase-Glo® assay kits
(Promega, Wisconsin, USA) according to the manu-
facturer’s instructions. Luminescence was measured 45
min after incubation with Caspase Glo® reagent using a
Luminoscan Ascent luminometer (Thermo LabSystems
Inc., Massachusetts, USA). Luminescence signal for trea-
ted samples were normalized to vehicle-treated samples
to express a fold change increase in caspase activity.
Supravital staining with acridine orange
Cells were seeded on glass coverslips and treated for 24
h with IC50 AJ-5 or vehicle and then stained with 2 µg/mL
acridine orange (Michrome No. 714; Edward Gurr
Ltd, UK), which was added directly to the medium, for 15
min at RT in the dark. Coverslips were mounted on
glass slides and visualized and imaged as described for
immunofluorescence.
Single-cell autophagosome flux analyses
The autophagy steady-state variables were measured in
RD cells treated with IC50 AJ-5 for 48 h. The autopha-
gosome flux was calculated from the rate of autophago-
some accumulation as previously described60. Briefly, this
was determined after the complete inhibition of fusion
between autophagosomes and lysosomes using 400 nM
bafilomycin A1 (B0025; LKT Laboratories Inc., Minne-
sota, USA).
Cells were transfected with a GFP-LC3 construct using
Lipofectamine 3000 (L3000001; Thermo Fisher Scientific)
according to the manufacturer’s instructions and main-
tained for 2 days in order to achieve high levels of GFP-
LC3 expression. Thereafter, cells were harvested by
trypsinization and seeded into an eight-chamber cover-
slip-based dish (155411 Nunc™ Lab-Tek™; Thermo Fisher
Scientific) to achieve 60% confluency after which they
were treated with IC50 AJ-5 for 48 h.
Autophagosome, autolysosome and lysosome pool size
was assessed by supplementing the culture media with 25
nM LysoTracker Red (L7528; Thermo Fisher Scientific) 2
h prior to image acquisition. An LSM 780 confocal with
ELYRA S.1 Superresolution platform (Carl Zeiss) was
used for image acquisition. The eight-chamber dish was
placed in a heated chamber maintained at 5% CO2 that
encased the microscope objective. An LCI Plan-
Apochromat ×63/1.4 oil DIC M27 objective was used
and samples were excited with an Argon multiline laser
25 mW at 488 and 514 nm with appropriate beam splitters
and GaAsP detector 32+2 PMT. Multiple z layers were
acquired with 1 µM step width. Laser power and electron
gain were set to achieve an optimal signal to noise ratio
without causing photo-toxicity. Images were processed
using ZEN 2011 imaging software (Carl Zeiss) and the
maximum intensity projections were exported to Fiji
software61 for further analysis60.
Pharmacokinetics studies of AJ-5 in healthy mice
All studies and procedures were conducted with prior
approval of the Animal Ethics Committee of the Uni-
versity of Cape Town (Protocol 012/049) in accordance
with the South African National Standard (SANS
10386:008) for the Care and Use of Animals for Scientific
Purposes62, and guidelines from the Department of
Health63.
Pharmacokinetic parameters of AJ-5 were determined
after IV, IP and PO dosing to MF1 nude mice randomly
divided into groups. AJ-5 was prepared in the respective
formulations immediately prior to dosing. For the IV
group, the compound was made up in a mixture of 10%
DMSO and 90% of an IV mixture, which consisted of 60%
propylene glycol, 10% ethanol and 30% polyethylene gly-
col. For the PO group, AJ-5 was dissolved in DMSO and a
hydroxypropylmethylcellulose solution (0.5% in water)
containing 0.2% Tween 80 in a ratio of 1:9. For the IP
group, AJ-5 was dissolved in 10% DMSO and 90% phos-
phate buffer solution. Mice were permitted access to food
and water ad libitum. AJ-5 was administered (100 μL) by
oral gavage at a dose of 20 mg/kg (n= 3), intravenously
into the penile dorsal vein at a dose of 2 mg/kg (n= 2) and
intraperitoneally at a dose of 2 mg/kg (n= 3).
Blood samples (20 μL per sample) were collected by tail
tip bleeding in lithium heparin tubes at predetermined
time points to evaluate the kinetic profile over 24 h.
Samples were stored at −80 °C until analysis. Blood
samples together with calibration standards and quality
controls were quantified using inductively coupled plasma
mass spectrometry. All results reported are for palladium
(Pd). Pharmacokinetic parameters of the AJ-5 complex
were determined using non-compartmental analysis in PK
Solutions 2.0 (Summit Research Systems, Montrose CO,
USA).
Statistical analyses
All data were obtained from at least three independent
experiments (unless otherwise stated) with error bars
representing standard error of the mean (SEM). Data were
analysed using GraphPad Prism version 6.0 (GraphPad
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Software) and a parametric unpaired t-test was per-
formed. Significance was accepted at *p < 0.05,**p < 0.01
and ***p < 0.001.
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